PTC Therapeutics, Inc.PTCTNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.11% | -30.58% | +459.73% | -4.19% | +7.23% |
| Gross Profit Growth | -0.61% | -1.93% | +495.38% | -2.17% | -48.87% |
| EBITDA Growth | +0.00% | +0.00% | +8320.54% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | -5304.78% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.05% | +2.24% | +2.12% | +1.86% | +5.94% |
| Weighted Average Shares Diluted Growth | +2.05% | +2.24% | +12.93% | +1.86% | +13.25% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +1129.64% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +13434.65% | +0.00% | +0.00% |
| Receivables Growth | +20.67% | -1.41% | +6.49% | +4.80% | +1.55% |
| Inventory Growth | -0.23% | -24.15% | -27.89% | +7.02% | +47.71% |
| Asset Growth | +46.22% | -10.06% | +48.38% | +37.46% | +43.50% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -43.18% | +10.85% | -7.55% | -1.86% | +522.69% |
| R&D Expense Growth | -1.71% | +2.82% | -6.16% | -14.51% | -37.95% |
| SG&A Expenses Growth | -9.19% | +11.00% | +10.49% | +22.68% | +14.42% |